ArticleNeoplasia (New York, N.Y.)2014

Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.

Pradip De et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.